Robert Baltera Jr. - 22 Nov 2022 Form 4 Insider Report for Frazier Lifesciences Acquisition Corp

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 22 Nov 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Nov 2022, 15:25:02 UTC
Prior SEC filing: 03 Jun 2022
Next SEC filing: 11 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Robert Baltera

Key filing fact

Robert Baltera Jr. filed Form 4 for Frazier Lifesciences Acquisition Corp on 23 Nov 2022.

Key facts

This page summarizes Robert Baltera Jr.'s Form 4 filing for Frazier Lifesciences Acquisition Corp.
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Nov 2022, 15:25.

Change

Previous filing in this sequence was filed on 03 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FLAC transaction Derivative

Class B Ordinary Shares

Options Exercise

Transaction value
Shares: -30,000
Change %: -100%
Price
Shares after: 0
Date: 22 Nov 2022
Ownership: Direct
Underlying class: Class A Ordinary Shares
Underlying amount: 30,000
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Robert Baltera Jr. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022.